COVID-19 has challenged the medical world in many ways. The speed with which the highly infectious virus has cut through traditional medical roadblocks has necessitated immediate and decisive actions. Collaborations between academic scientists, government, and industry have forged strong efforts to generate protective measures against the outbreak. Many companies have stepped forward with innovative products to help in the fight against the virus as well. Here are a few new products and solutions.
First line medical care providers are the initial point of contact with patients, and the high transmissibility of the virus has made the use of personal protective equipment (PPE) a strict requirement. Despite this importance, healthcare systems have experienced shortages of PPE, which in turn have led to the development of contingency strategies.
One such solution has been the increased use of mask sterilization systems to allow decontamination and re-use of N95 respirators.
Innovative thinking has led the re-deployment of existing technology for use in sterilization applications.
Initial testing efforts were blunted by process issues and the paucity of available and approved testing technologies. As new concepts were developed and existing technologies were re-designed, testing and diagnostic solutions have assumed the top position in the ongoing fight against COVID-19.
There are currently over 100 in vitro diagnostic tests and commercial testing kits available with EUA designation. These include technologies based on: real-time PCR (RT-PCR) detection of SARS-COV-2 nucleic acid panels or markers, quantitative detection of IgM, IgG, or combined viral antibodies, and other techniques. The use of these “high-complexity” or “moderate-complexity” tests are suited for CLIA-designated commercial laboratories or patient care settings, although some tests may be performed at small labs with CLIA-except status.
Although early detection is key, tests oriented towards detecting antibody responses are needed to confirm infection and to assess the generation of immunity to the virus. A growing number of serology tests have entered the market, including those from companies proficient in the area of antibody-based diagnostics. Expertise in this testing landscape is especially relevant, considering the possibility for inaccuracy in antibody tests.
Initial generation of IgM and IgA antibodies can indicate exposure. However, a sustained response gives rise to IgG antibodies in the blood serum. Measuring all three may increase the specificity of COVID-19 detection and minimize false positives.
Effective testing requires effective sample collection and processing products. Nasopharyngeal and oropharyngeal swabs (e.g. throat swabs) are required for RT-PCR testing in order to obtain the appropriate amount or virus from secreted materials. Blood draw and treatment tubes are needed for blood sample collection and serum or plasma separation. Virus transport media is required for sample preservation during shipping to testing locations. Labels and sample management solutions are a necessity in all matters relating to testing.
The severity and the scale of the COVID-19 outbreak has necessitated the deployment of innovative safety and sample handling devices. Pathogen containment workstations are intended for sample handling and test workup, while UV-light treatment workstations provide pathogen eradication solutions. Automated liquid handling systems have been engineered for viral applications and include high-throughput testing workstations and sample management systems.
Both workstations are paired with necessary software and consumables, and can be configured to work with any supplier’s assay chemistry.
Many other innovative safety and storage solutions are emerging in the fight against COVID-19. The therapeutic and vaccine development areas are witnessing significant growth in lab instrument solutions as well. Further products and new technologies will be detailed in subsequent articles, offering a closer look at their importance in treatment of COVID-19 and for the prevention of possible future outbreaks.